Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results. J of Skin. 2017;1(3.1):s102. doi:10.25251/skin.1.supp.101